Clinical trials: Plaque Type Psoriasis
Plaque-type Psoriasis
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
The purpose of this study was to provide long term clinical data for the compound for the treatment of the indication of moderate to severe chronic plaque-type psoriasis.
- Trial name
- NCT01132612
- Testing
- AIN457
- Where
- 57 sites in United States, France and 5 more
- Volunteers
- 275 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Plaque Type Psoriasis
Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis
This study assessed efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis
- Trial name
- NCT02074982
- Testing
- AIN457 300 mg, ustekinumab 45/90 mg
- Where
- 137 sites in United States, Australia and 22 more
- Volunteers
- 676 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Type Psoriasis
Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira
The aim of the study is to demonstrate equivalent efficacy and similarity in the safety profile of GP2017 and Humira® in patients with moderate to severe chronic plaque-type psoriasis.
- Trial name
- ADACCESS (NCT02016105)
- Testing
- GP2017 Adalimumab, Humira ® Adalimumab
- Where
- 79 sites in United States, Bulgaria and 2 more
- Volunteers
- 465 people
- Sponsor
- Sandoz
Psoriasis, Plaque-type Psoriasis
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
This study is designed to evaluate the proportion of patients achieving reversal of chronic plaque psoriasis at week 4 and 12 following multiple doses of secukinumab administered subcutaneously (sc) compared to placebo.
- Trial name
- NCT01537432
- Testing
- secukinumab
- Where
- 12 sites in United States
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Plaque-type Psoriasis
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body…
- Trial name
- NCT00941031
- Testing
- AIN457, AIN457A
- Where
- 62 sites in United States, France and 5 more
- Volunteers
- 404 people
- Sponsor
- Novartis Pharmaceuticals
Moderate to Severe Plaque-type Psoriasis
Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens
This study will assess the safety and efficacy of two different doses and two different dose regimens of subcutaneous secukinumab in patients that have moderate to severe, chronic, plaque-type psoriasis.
- Trial name
- SCULPTURE (NCT01406938)
- Testing
- AIN457 150mg, AIN457 300mg
- Where
- 131 sites in United States, Austria and 14 more
- Volunteers
- 967 people
- Sponsor
- Novartis Pharmaceuticals
Plaque-type Psoriasis
Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis
The study will assess the safety and efficacy of intravenous (10mg/kg) and subcutaneous (300mg) secukinumab in moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab.
- Trial name
- STATURE (NCT01412944)
- Testing
- secukinumab 150mg, secukinumab 10mg/kg i.v. regimen
- Where
- 27 sites in United States, Austria and 6 more
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Plaque-type Psoriasis
A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body…
- Trial name
- NCT01071252
- Testing
- AIN457
- Where
- 19 sites in United States, Canada and 4 more
- Volunteers
- 125 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Type Psoriasis
SHP-141C in Plaque Type Psoriasis
The purpose of this study is to assess the safety, tolerability and clinical activity of the SHP-141C topical cream formulations in patients with plaque type psoriasis.
- Trial name
- NCT01646567
- Testing
- SHP-141C, Betamethasone Valerate, Calcipotriol
- Where
- Australia
- Volunteers
- 14 people
- Sponsor
- TetraLogic Pharmaceuticals
Plaque-Type Psoriasis
A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis
The purpose of the study is to determine the efficacy and safety of two different forms of a topical steroid (clobetasol propionate) in patients with plaque-type psoriasis.
- Trial name
- NCT00852761
- Testing
- Olux-E Foam, Clobex lotion
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Stiefel, a GSK Company
Plaque-type Psoriasis
Study of Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis
Low doses of topically administered vitamin D analogs have been shown to have an anti-psoriatic effect without the risk of hypercalcemia.
- Trial name
- NCT00625326
- Testing
- COL-121, 50 µg/g Calcipotriene Ointment
- Where
- 20 sites in United States
- Volunteers
- 321 people
- Sponsor
- Deltanoid Pharmaceuticals